Patented Myopia Treatment Is Obvious, Petitioner Tells Board
ALEXANDRIA, Va. — In a Feb. 17 petition for inter partes review (IPR), a pharmaceutical company maintains that the Patent Trial and Appeal Board should cancel 19 claims of a patented...To view the full article, register now.
Already a subscriber? Click here to view full article